Clinical trials: Atheroscleroses
Atherosclerosis, Coronary Artery Disease
XIENCE V® EXCEED: Evaluation of XIENCE V® Catheterization Lab Endpoints and Excellence in Delivery
This trial is to assess physician-determined XIENCE V® EECSS acute performance, deliverability and resource utilization in the catheterization lab during commercial use by various physicians with a range of coronary stenting…
- Trial name
- EXCEED (NCT00731237)
- Where
- 44 sites in United States
- Volunteers
- 2,517 people
- Sponsor
- Abbott Medical Devices
Coronary Stenosis, Acute Coronary Syndrome
Systemic, Pancoronary and Local Coronary Vulnerability
The aim of the VIP study is to investigate the impact of vulnerability markers (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and vulnerability mapping for pancoronary vulnerability, and…
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques
- Trial name
- VIP (NCT03606330)
- Testing
- Cardiac imaging tests, Venous blood sample collection
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Diabetes Mellitus, Type 2, Peripheral Arterial Disease
A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes
This study is done to see if semaglutide has an effect on walking ability compared with placebo (dummy medicine) in people with peripheral arterial disease (PAD) and type 2 diabetes.
- Trial name
- STRIDE (NCT04560998)
- Testing
- Semaglutide
- Where
- 283 sites in United States, Austria and 19 more
- Volunteers
- 792 people
- Sponsor
- Novo Nordisk A/S
Atherosclerotic Cardiovascular Disease, Hypercholesterolemia
A Real-world Study of Inclisiran Adherence, Treatment Patterns, Patient Characteristics, and Effectiveness in ASCVD Patients With Hypercholesterolemia, ASCVD-risk Equivalent Patients With Hypercholesterolemia and Familial Hypercholesterolemia
This was a descriptive, non-interventional, retrospective cohort study among patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia, ASCVD-risk equivalent (ASCVD-RE) or familial hypercholesterolemia…
- Trial name
- NCT06507852
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Novartis
Peripheral Arterial Disease
Safety and Effectiveness of Jetstream Atherectomy System (J-SUPREME II)
The purpose of this study is to evaluate the safety and effectiveness of the Jetstream Atherectomy System for the treatment of Japanese patients with symptomatic occlusive atherosclerotic lesions in native superficial femoral…
- Trial name
- NCT03847233
- Testing
- Jetstream Atherectomy System
- Where
- 5 sites in Japan
- Volunteers
- 31 people
- Sponsor
- Boston Scientific Corporation
Peripheral Arterial Disease (PAD)
A Non-significant Risk Clinical Study: Changes in Perfusion After Therapeutic Ultrasound in Patients With PAD
All evaluable subjects will receive VibratoSleeve therapeutic ultrasound (TUS) treatments. The device will be programmed to deliver TUS at a pre-determined level.
- Trial name
- NCT05149664
- Testing
- Therapeutic ultrasound (TUS)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vibrato Medical, Inc.
Peripheral Arterial Disease
Safety and Feasibility of the Shockwave Lithoplasty® System for the Treatment of Peripheral Vascular Stenosis
To observe early safety and performance of the Shockwave Medical Lithoplasty® System (specifically, Lithoplasty® Catheters: 2.5 x 60mm, 2.75 x 60mm, 3.0 x 60mm, 3.25 x 60mm, and 3.5 x 60mm) in subjects to demonstrate that the…
- Trial name
- BTK (NCT02911623)
- Testing
- Shockwave Lithoplasty® System
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- Shockwave Medical, Inc.
Atherosclerosis, Ischemia
Trial to Assess the Ocular Safety of Vorapaxar (SCH 530348) in Participants With Atherosclerosis (Study P05183)
This study is designed to evaluate the long-term ocular safety of SCH 530348 (vorapaxar) in participants with established atherosclerotic disease who are enrolled into the TRA 2°P - TIMI 50 Study (P04737) (NCT00526474).
- Conditions
- Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident
- Trial name
- NCT00617123
- Testing
- Vorapaxar 2.5 mg
- Volunteers
- 258 people
- Sponsor
- Merck Sharp & Dohme LLC
Femoral Artery Stenosis, Femoral Artery Occlusion
A Single Arm Trial Evaluating the BARD Lutonix Drug-Coated Balloon (LTX DCB) for Treatment of Femoropopliteal Arteries
To assess the safety and efficacy of the BARD LTX DCB for treatment of stenosis or occlusion of the superficial femoral and popliteal arteries.
- Conditions
- Femoral Artery Stenosis, Femoral Artery Occlusion, Stenosis of Popliteal Arteries, Occlusion of Popliteal Arteries
- Trial name
- NCT02720003
- Testing
- LTX DCB
- Where
- 14 sites in China
- Volunteers
- 148 people
- Sponsor
- C. R. Bard
Peripheral Arterial Disease
Post-Market Study of ZENFLEX Pro Stent for Femoropopliteal Artery Lesions
This is a prospective, multi-center, single-arm post-market study evaluating the safety and effectiveness of the ZENFLEX Pro™ Drug-eluting Stent in treating femoropopliteal artery stenosis or occlusion.
- Trial name
- NCT07049120
- Testing
- ZENFLEX Pro™ Peripheral Drug-eluting Stent System
- Where
- Poland
- Volunteers
- 153 people
- Sponsor
- Zhejiang Zylox Medical Device Co., Ltd.
Hypercholesterolemia, Atherosclerosis
Ezetimibe Plus Simvastatin Versus Simvastatin in Patients With Hypercholesterolemia and Coronary Risk Factors (P03405)
The study was designed to assess whether 6 weeks of co-administration of ezetimibe and simvastatin is more effective than simvastatin monotherapy in allowing patients in the CHD risk strata of the NCEP III guidelines to achieve…
- Trial name
- NCT00651014
- Testing
- Ezetimibe
- Volunteers
- 82 people
- Sponsor
- Organon and Co
Atherosclerosis
Single Ascending Dose Safety Study of BMS-962476 in Healthy Subjects and Patients With Elevated Cholesterol on Statins
To obtain safety and tolerability information in healthy subjects is administered as a single dose
- Trial name
- NCT01587365
- Testing
- BMS-962476
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Homozygous Familial Hypercholesterolemia (HoFH)
A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501
This long-term observational study is designed to follow subjects who, during another Clinical Study, received gene therapy treatment used to treat their Homozygous Familial Hypercholesterolemia (HoFH) disease.
- Trial name
- NCT04080050
- Testing
- Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy
- Where
- 6 sites in United States, Canada and 1 more
- Volunteers
- 8 people
- Sponsor
- REGENXBIO Inc.
Peripheral Artery Disease (PAD); Intermittent Claudication
Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication
This study is designed to determine whether LLG783 displays the clinical safety and efficacy profile, after multiple i.v. doses, to support further development in patients with PAD and intermittent claudication.
- Trial name
- PAD PoC (NCT03194776)
- Testing
- LLG783
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Peripheral Arterial Disease (PAD)
Zilver® Flex™ Vascular Stent Study
This study is intended to evaluate the long-term effectiveness of treatment of de novo or restenotic lesions of the above-the-knee femoropopliteal artery using the Zilver® Flex™ Vascular Stent which has received the CE mark for…
- Trial name
- NCT00827619
- Testing
- Zilver® Flex™ Vascular Stent
- Where
- 3 sites in Germany
- Volunteers
- 110 people
- Sponsor
- Cook Group Incorporated
Peripheral Arterial Disease
Edoxaban in Peripheral Arterial Disease
This study is a randomized, open-label, blinded endpoint, parallel-group, active-control, multi-center, proof-of-concept study in subjects with Peripheral Arterial Disease (PAD), designed to assess the safety and potential…
- Trial name
- ePAD (NCT01802775)
- Testing
- edoxaban, Clopidogrel, Aspirin
- Where
- 42 sites in United States, Austria and 5 more
- Volunteers
- 203 people
- Sponsor
- Daiichi Sankyo
Peripheral Arterial Disease, Arterial Puncture
The Safety and Efficacy of the Suture-Mediated Closure System
This was a prospective, multicenter, randomized, controlled, non-inferiority clinical study with the primary objective of validating the safety and efficacy of the Suture-Mediated Closure System for percutaneous closure of the…
- Trial name
- NCT05841836
- Testing
- the Suture-Mediated Closure System, Perclose ProGlide Suture-Mediated Closure System
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Zhejiang Zylox Medical Device Co., Ltd.
Cardiovascular Diseases, Atherosclerosis
Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
Phase 2 study to evaluate the efficacy, safety and tolerability of SLN360 administered subcutaneously (SC) compared with placebo in adult participants with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular…
- Conditions
- Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
- Trial name
- NCT05537571
- Testing
- SLN360
- Where
- 29 sites in Australia, Czechia and 5 more
- Volunteers
- 180 people
- Sponsor
- Silence Therapeutics plc
Atherosclerotic Cardiovascular Disease
A Retrospective Cohort Study Evaluating Major Adverse Cardiovascular Events and Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease Without Prior Ischemic Events (OPTIMUS RISK - Netherlands)
This study will evaluate cardiovascular outcomes among individuals with clinically established atherosclerotic cardiovascular disease (ASCVD) who have not previously experienced a myocardial infarction (MI) or ischemic stroke.
- Trial name
- NCT07905508
- Where
- Netherlands
- Volunteers
- 180,000 people
- Sponsor
- Sanofi
Atherosclerosis of Autologous Vein Coronary Artery Bypass Graft(s)
The eMESH 1 Feasibility Study
Multi-center, dual cohort (randomized and single vessel) study designed to demonstrate feasibility, initial safety and performance of the Kips Bay Medical, Inc.
- Trial name
- eMESH 1 (NCT01676376)
- Testing
- eSVS Mesh treated saphenous vein graft, Control saphenous vein graft
- Where
- 15 sites in United States, Czechia and 5 more
- Volunteers
- 120 people
- Sponsor
- Kips Bay Medical, Inc.